These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18000367)

  • 21. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
    Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
    Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. X-linked inheritance of Fanconi anemia complementation group B.
    Meetei AR; Levitus M; Xue Y; Medhurst AL; Zwaan M; Ling C; Rooimans MA; Bier P; Hoatlin M; Pals G; de Winter JP; Wang W; Joenje H
    Nat Genet; 2004 Nov; 36(11):1219-24. PubMed ID: 15502827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia.
    Meyer S; White DJ; Will AM; Eden T; Sim A; Brown R; Strathdee G
    Br J Haematol; 2006 Jul; 134(1):61-3. PubMed ID: 16803569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Fanconi anaemia/BRCA pathway.
    D'Andrea AD; Grompe M
    Nat Rev Cancer; 2003 Jan; 3(1):23-34. PubMed ID: 12509764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
    Lyakhovich A; Surralles J
    Cancer Lett; 2006 Jan; 232(1):99-106. PubMed ID: 16246487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
    Wang Z; Li M; Lu S; Zhang Y; Wang H
    Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.
    Türke C; Horn S; Petto C; Labudde D; Lauer G; Wittenburg G
    Int J Oncol; 2017 Jun; 50(6):2207-2220. PubMed ID: 28440438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.
    Knowles MA; Aveyard JS; Taylor CF; Harnden P; Bass S
    Cancer Lett; 2005 Jul; 225(1):121-30. PubMed ID: 15922864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment.
    Martinez A; Hinz JM; Gómez L; Molina B; Acuña H; Jones IM; Frias S; Coleman MA
    Mutat Res; 2008 Oct; 656(1-2):1-7. PubMed ID: 18647660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoter analysis of epigenetically controlled genes in bladder cancer.
    Veerla S; Panagopoulos I; Jin Y; Lindgren D; Höglund M
    Genes Chromosomes Cancer; 2008 May; 47(5):368-78. PubMed ID: 18196590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    Stecklein SR; Jensen RA
    Transl Res; 2012 Sep; 160(3):178-97. PubMed ID: 22683426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.
    Lyakhovich A; Surralles J
    Cancer Lett; 2007 Oct; 256(2):186-95. PubMed ID: 17643815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
    Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
    Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fancf-deficient mice are prone to develop ovarian tumours.
    Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H
    J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
    Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
    Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation.
    Zanier R; Briot D; Dugas du Villard JA; Sarasin A; Rosselli F
    Oncogene; 2004 Jun; 23(29):5004-13. PubMed ID: 15077170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Fanconi anemia pathway limits the severity of mutagenesis.
    Hinz JM; Nham PB; Salazar EP; Thompson LH
    DNA Repair (Amst); 2006 Aug; 5(8):875-84. PubMed ID: 16815103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microarray mRNA expression analysis of Fanconi anemia fibroblasts.
    Galetzka D; Weis E; Rittner G; Schindler D; Haaf T
    Cytogenet Genome Res; 2008; 121(1):10-3. PubMed ID: 18544920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.